Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if there is a difference in how well the standard
MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in
preventing CMV infections in kidney transplant recipients who are at risk for this type of
infection, while also assessing the tolerability of these two regimens. The two medication
regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection)
vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent
HSV infection).